Published in Oncogene on April 03, 2003
Prediction of graft-versus-host disease in humans by donor gene-expression profiling. PLoS Med (2007) 1.40
TGFBI expression is associated with a better response to chemotherapy in NSCLC. Mol Cancer (2010) 1.11
Two novel VHL targets, TGFBI (BIGH3) and its transactivator KLF10, are up-regulated in renal clear cell carcinoma and other tumors. Biochem Biophys Res Commun (2008) 1.10
Angiostatic peptides use plasma fibronectin to home to angiogenic vasculature. Proc Natl Acad Sci U S A (2005) 1.10
The RUNX1 transcription factor is expressed in serous epithelial ovarian carcinoma and contributes to cell proliferation, migration and invasion. Cell Cycle (2013) 1.08
Effects of combined treatment with rapamycin and cotylenin A, a novel differentiation-inducing agent, on human breast carcinoma MCF-7 cells and xenografts. Breast Cancer Res (2005) 1.00
Atrioventricular valve development: new perspectives on an old theme. Differentiation (2012) 0.98
Vascular complications and diabetes: current therapies and future challenges. J Ophthalmol (2012) 0.95
Transforming growth Factor-Beta-Induced Protein (TGFBI)/(βig-H3): a matrix protein with dual functions in ovarian cancer. Int J Mol Sci (2012) 0.93
Detection of differentially expressed basal cell proteins by mass spectrometry. Mol Cell Proteomics (2009) 0.92
ß3 integrin modulates transforming growth factor beta induced (TGFBI) function and paclitaxel response in ovarian cancer cells. Mol Cancer (2012) 0.92
The role of TGFBI in mesothelioma and breast cancer: association with tumor suppression. BMC Cancer (2012) 0.90
C-terminal fragment of transforming growth factor beta-induced protein (TGFBIp) is required for apoptosis in human osteosarcoma cells. Matrix Biol (2009) 0.87
TGFBI (βIG-H3) is a diabetes-risk gene based on mouse and human genetic studies. Hum Mol Genet (2014) 0.83
TGFBI expression is an independent predictor of survival in adjuvant-treated lung squamous cell carcinoma patients. Br J Cancer (2014) 0.83
Altered protein conformation and lower stability of the dystrophic transforming growth factor beta-induced protein mutants. Mol Vis (2013) 0.82
Denaturation and solvent effect on the conformation and fibril formation of TGFBIp. Mol Vis (2009) 0.81
Inhibition of TGFBIp expression reduces lymphangiogenesis and tumor metastasis. Oncogene (2015) 0.80
Construction of eukaryotic plasmid expressing human TGFBI and its influence on human corneal epithelial cells. Int J Ophthalmol (2012) 0.78
Investigation of the influence of Arg555Trp and Thr538Pro TGFBI mutations on C-terminal cleavage and cell endoplasmic reticulum stress. Mol Vis (2012) 0.77
The role of TGFBI (βig-H3) in gastrointestinal tract tumorigenesis. Mol Cancer (2015) 0.77
Expression patterns of betaig-h3 in chondrocyte differentiation during endochondral ossification. Exp Mol Med (2008) 0.76
Crystallization and preliminary crystallographic analysis of the fourth FAS1 domain of human BigH3. Acta Crystallogr Sect F Struct Biol Cryst Commun (2007) 0.76
Bigh3 silencing increases retinoblastoma tumor growth in the murine SV40-TAg-Rb model. Oncotarget (2017) 0.75
Macrophage TGF-β1 and the Proapoptotic Extracellular Matrix Protein BIGH3 Induce Renal Cell Apoptosis in Prediabetic and Diabetic Conditions. Int J Clin Med (2016) 0.75
Ameliorative Effect of Vicenin-2 and Scolymoside on TGFBIp-Induced Septic Responses. Inflammation (2015) 0.75
Telomere length and the risk of lung cancer. Cancer Sci (2008) 2.35
Genome-wide association analysis identifies new lung cancer susceptibility loci in never-smoking women in Asia. Nat Genet (2012) 2.26
Runx2 control of organization, assembly and activity of the regulatory machinery for skeletal gene expression. Oncogene (2004) 2.25
Cell growth regulatory role of Runx2 during proliferative expansion of preosteoblasts. Cancer Res (2003) 2.20
Bone morphogenetic protein-2 stimulates Runx2 acetylation. J Biol Chem (2006) 2.15
The bone-specific expression of Runx2 oscillates during the cell cycle to support a G1-related antiproliferative function in osteoblasts. J Biol Chem (2005) 1.93
The 5p15.33 locus is associated with risk of lung adenocarcinoma in never-smoking females in Asia. PLoS Genet (2010) 1.90
Stem cell factor SALL4 represses the transcriptions of PTEN and SALL1 through an epigenetic repressor complex. PLoS One (2009) 1.77
The protein kinase C pathway plays a central role in the fibroblast growth factor-stimulated expression and transactivation activity of Runx2. J Biol Chem (2002) 1.66
Regulation of the chondrocyte phenotype by beta-catenin. Development (2002) 1.63
Dlx5 specifically regulates Runx2 type II expression by binding to homeodomain-response elements in the Runx2 distal promoter. J Biol Chem (2005) 1.56
Identification of motifs in the fasciclin domains of the transforming growth factor-beta-induced matrix protein betaig-h3 that interact with the alphavbeta5 integrin. J Biol Chem (2002) 1.53
TGFBIp/betaig-h3 protein: a versatile matrix molecule induced by TGF-beta. Int J Biochem Cell Biol (2007) 1.51
IQGAP1 stimulates proliferation and enhances tumorigenesis of human breast epithelial cells. J Biol Chem (2007) 1.46
Tumor targetability and antitumor effect of docetaxel-loaded hydrophobically modified glycol chitosan nanoparticles. J Control Release (2008) 1.44
Somatic mutations in epidermal growth factor receptor signaling pathway genes in non-small cell lung cancers. J Thorac Oncol (2010) 1.43
Transforming growth factor-beta-induced protein (TGFBIp/beta ig-h3) activates platelets and promotes thrombogenesis. Blood (2009) 1.42
Leptin gene expression and serum leptin levels in zinc deficiency: implications for appetite regulation in rats. J Med Food (2003) 1.40
Restoration of peri-implant defects in immediate implant installations by Choukroun platelet-rich fibrin and silk fibroin powder combination graft. Oral Surg Oral Med Oral Pathol Oral Radiol Endod (2010) 1.40
Targeting prion-like protein doppel selectively suppresses tumor angiogenesis. J Clin Invest (2016) 1.39
The dynamic organization of gene-regulatory machinery in nuclear microenvironments. EMBO Rep (2005) 1.38
Establishment of a near-standard two-dimensional human urine proteomic map. Proteomics (2004) 1.38
Maintenance of differentiated phenotype of articular chondrocytes by protein kinase C and extracellular signal-regulated protein kinase. J Biol Chem (2001) 1.38
Betaig-h3 supports keratinocyte adhesion, migration, and proliferation through alpha3beta1 integrin. Biochem Biophys Res Commun (2002) 1.38
Hydrophobically modified glycol chitosan nanoparticles-encapsulated camptothecin enhance the drug stability and tumor targeting in cancer therapy. J Control Release (2008) 1.38
Tumor-homing multifunctional nanoparticles for cancer theragnosis: Simultaneous diagnosis, drug delivery, and therapeutic monitoring. J Control Release (2010) 1.37
DNMT3B polymorphisms and risk of primary lung cancer. Carcinogenesis (2004) 1.37
Tetraspanin TM4SF5 mediates loss of contact inhibition through epithelial-mesenchymal transition in human hepatocarcinoma. J Clin Invest (2008) 1.35
Biodistribution and anti-tumor efficacy of doxorubicin loaded glycol-chitosan nanoaggregates by EPR effect. J Control Release (2003) 1.34
Cell-permeable and biocompatible polymeric nanoparticles for apoptosis imaging. J Am Chem Soc (2006) 1.33
Vascular endothelial growth factor gene polymorphisms associated with prognosis for patients with colorectal cancer. Clin Cancer Res (2008) 1.32
Self-assembled nanoparticles based on glycol chitosan bearing hydrophobic moieties as carriers for doxorubicin: in vivo biodistribution and anti-tumor activity. Biomaterials (2006) 1.32
Identification of the alphavbeta3 integrin-interacting motif of betaig-h3 and its anti-angiogenic effect. J Biol Chem (2003) 1.31
The Salmonella SPI2 effector SseI mediates long-term systemic infection by modulating host cell migration. PLoS Pathog (2009) 1.30
Vascular endothelial growth factor gene polymorphisms and risk of primary lung cancer. Cancer Epidemiol Biomarkers Prev (2005) 1.29
Antitumor efficacy of cisplatin-loaded glycol chitosan nanoparticles in tumor-bearing mice. J Control Release (2007) 1.29
Functional architecture of the nucleus: organizing the regulatory machinery for gene expression, replication and repair. Trends Cell Biol (2003) 1.29
A combination graft of low-molecular-weight silk fibroin with Choukroun platelet-rich fibrin for rabbit calvarial defect. Oral Surg Oral Med Oral Pathol Oral Radiol Endod (2010) 1.25
Beta ig-h3 promotes renal proximal tubular epithelial cell adhesion, migration and proliferation through the interaction with alpha3beta1 integrin. Exp Mol Med (2004) 1.23
PTEN mutations and relationship to EGFR, ERBB2, KRAS, and TP53 mutations in non-small cell lung cancers. Lung Cancer (2009) 1.22
Ionizing radiation induces cellular senescence of articular chondrocytes via negative regulation of SIRT1 by p38 kinase. J Biol Chem (2009) 1.20
Wnt-7a causes loss of differentiated phenotype and inhibits apoptosis of articular chondrocytes via different mechanisms. J Biol Chem (2004) 1.20
EGFR, ERBB2, and KRAS mutations in Korean non-small cell lung cancer patients. Cancer Genet Cytogenet (2007) 1.20
Polymorphisms in the survivin gene and the risk of lung cancer. Lung Cancer (2007) 1.19
Increased miR-708 expression in NSCLC and its association with poor survival in lung adenocarcinoma from never smokers. Clin Cancer Res (2012) 1.18
Effect of polymer molecular weight on the tumor targeting characteristics of self-assembled glycol chitosan nanoparticles. J Control Release (2007) 1.18
Erythropoietin decreases renal fibrosis in mice with ureteral obstruction: role of inhibiting TGF-beta-induced epithelial-to-mesenchymal transition. J Am Soc Nephrol (2007) 1.18
Smart nanocarrier based on PEGylated hyaluronic acid for cancer therapy. ACS Nano (2011) 1.18
Four novel RUNX2 mutations including a splice donor site result in the cleidocranial dysplasia phenotype. J Cell Physiol (2006) 1.16
Brain-type creatine kinase has a crucial role in osteoclast-mediated bone resorption. Nat Med (2008) 1.16
Tumor-targeting peptide conjugated pH-responsive micelles as a potential drug carrier for cancer therapy. Bioconjug Chem (2010) 1.16
Molecular properties of wild-type and mutant betaIG-H3 proteins. Invest Ophthalmol Vis Sci (2002) 1.14
Polymorphisms in the caspase-8 gene and the risk of lung cancer. Cancer Genet Cytogenet (2006) 1.14
Mechanism for phosphatidylserine-dependent erythrophagocytosis in mouse liver. Blood (2011) 1.13
Cancer-associated splicing variant of tumor suppressor AIMP2/p38: pathological implication in tumorigenesis. PLoS Genet (2011) 1.12
Self-assembled glycol chitosan nanoparticles for the sustained and prolonged delivery of antiangiogenic small peptide drugs in cancer therapy. Biomaterials (2008) 1.12
Expression of Runx2 transcription factor in non-skeletal tissues, sperm and brain. J Cell Physiol (2008) 1.11
Proteomic analysis of urinary exosomes from patients of early IgA nephropathy and thin basement membrane nephropathy. Proteomics (2011) 1.11
Transforming growth factor-beta-inducible gene-h3 (beta(ig)-h3) promotes cell adhesion of human astrocytoma cells in vitro: implication of alpha6beta4 integrin. Neurosci Lett (2003) 1.11
Aberrant methylation of E-cadherin and H-cadherin genes in nonsmall cell lung cancer and its relation to clinicopathologic features. Cancer (2007) 1.11
Targeting bladder tumor cells in vivo and in the urine with a peptide identified by phage display. Mol Cancer Res (2007) 1.10